S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News

$1.70
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.69
$1.75
50-Day Range
$1.29
$1.95
52-Week Range
$1.18
$2.72
Volume
18,799 shs
Average Volume
189,530 shs
Market Capitalization
$64.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Bolt Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
194.1% Upside
$5.00 Price Target
Short Interest
Bearish
6.40% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($1.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

541st out of 983 stocks

Pharmaceutical Preparations Industry

265th out of 486 stocks


BOLT stock logo

About Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
BOLT.O - | Stock Price & Latest News | Reuters
Bolt Biotherapeutics Inc Ordinary Shares
See More Headlines

BOLT Price History

BOLT Company Calendar

Last Earnings
3/29/2023
Today
6/04/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+194.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-88,100,000.00
Net Margins
-1,207.36%
Pretax Margin
-1,207.36%

Debt

Sales & Book Value

Annual Sales
$6.74 million
Book Value
$4.17 per share

Miscellaneous

Free Float
29,154,000
Market Cap
$64.28 million
Optionable
Not Optionable
Beta
1.02

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 68)
    CEO & Director
    Comp: $830.67k
  • Dr. Edgar G. Engleman M.D. (Age 77)
    Founder & Independent Director
    Comp: $31.58k
  • Mr. William P. QuinnMr. William P. Quinn (Age 52)
    CFO & Sec.
    Comp: $563.68k
  • Mr. Grant Yonehiro C.F.A. (Age 59)
    M.B.A., Chief Bus. Officer
    Comp: $519.98k
  • Dr. Edith A. Perez M.D. (Age 66)
    Chief Medical Officer
    Comp: $627.32k
  • Ms. Karen L. Bergman
    VP of Communications & Investor Relations
  • Mr. Wesley Burwell
    VP & Head of HR
  • Dr. Nathan Ihle Ph.D.
    Sr. VP of Pharmaceutical Operations
  • Dr. Ming Yin Ph.D.
    VP & Head of Biometrics













BOLT Stock - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings
or view top-rated stocks.

What is Bolt Biotherapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price targets for Bolt Biotherapeutics' shares. Their BOLT share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for BOLT
or view top-rated stocks among Wall Street analysts.

How have BOLT shares performed in 2023?

Bolt Biotherapeutics' stock was trading at $1.30 on January 1st, 2023. Since then, BOLT shares have increased by 30.8% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our BOLT earnings forecast
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.10. The company earned $1.41 million during the quarter, compared to analysts' expectations of $1.71 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 44.87% and a negative net margin of 1,207.36%.

Is Bolt Biotherapeutics a good dividend stock?

Bolt Biotherapeutics (NASDAQ:BOLT) pays an annual dividend of $0.36 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of Bolt Biotherapeutics own?
When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.21%), JPMorgan Chase & Co. (0.50%), Geode Capital Management LLC (0.47%), Bailard Inc. (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends
.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $1.70.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $64.28 million and generates $6.74 million in revenue each year. The company earns $-88,100,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:BOLT) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -